HDAC9 and Spinocerebellar ataxia type 3: Treatment with valproate, amongst other HDAC inhibitor compounds, has been demonstrated to positively modify disease phenotypes in other models of MJD including cellular models, Drosophila and mice [8, 24, 46, 50].